Macugen

This page contains recent news articles, when available, and an overview of Macugen but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

VIDEO: Staying Slim Is Environmentally Friendly, Macugen May ...  -  20 Apr 2009
From Maryland - According to research in the Archives of Ophthalmology, intravitreous injection with Macugen may help prevent vision loss. Insidermedicine

Intravitreous Pegaptanib Could Halt Vision Loss  -  ‎Apr 17, 2009‎
By Crystal Phend, Staff Writer, MedPage Today SAN FRANCISCO, April 17 -- Intravitreous injections of pegaptanib (Macugen) may help prevent further vision MedPage Today

Othera's Eye Drop to Cure ARMD Seems Promising But Too Early to Tell  -  ‎Apr 16, 2009‎
The exudative, or wet form, involves choroidal neovascularization and is treated with anti-VEGF treatments such as Avastin, Macugen or Lucentis. Gerson Lehrman Group

Research and Markets: Analysis of AERS Data on AMD Therapeutics  -  ‎Mar 31, 2009‎
This report provides a detailed analysis on the adverse events reported against the prescribed AMD drugs namely Lucentis, Macugen and Visudyne for the Business Wire (press release)

Riverside Eye Center offers the latest Surgical, Laser Eye Care ...  -  ‎Mar 15, 2009‎
These include diagnostic tools such as Ocular Coherence Tomography (OCT) and retina treatments such as Avastin, Macugen and Lucentis Injections for macular PRLog.Org (press release)

The People's Pharmacy  -  ‎Mar 4, 2009‎
A: The medicines are Macugen, Lucentis and Avastin. Ask your retinal specialist whether any of these is appropriate for you. Q: Thank you for your advice to Seattle Times

Battling cutaneous disease  -  ‎Mar 7, 2009‎
...such as Avastin and Lucentis (bevacizumab and ranibizumab, respectively, both made by Genentech), Macugen (pegaptanib, Pfizer) and Erbitux (cetuximab, Modern Medicine

Taking Stock in Pfizer Inc.  -  ‎Mar 9, 2009‎
Global Approvals of Fesoterodine (US), Maraviroc (Japan), Macugen (Japan), Rifabutin (Japan), Sutent (Japan), Champix (Japan), Genotropin (Japan), Seeking Alpha

Economic and Clinical Value: Key Drivers for New Product ...  -  ‎Mar 2, 2009‎
Less than one year after Visudyne achieved full patient reimbursement, Eyetech Inc.’s Macugen, a competitive product, was on the market. Medical Device Link (press release)

Restrictions lifted on drug for poor vision  -  Jan 21, 2009
These are called Lucentis and Macugen. Lucentis (also known as ranibizumab) is an injection that you have in your eye. A study of more than 700 people guardian.co.uk,

Macular degeneration  -  Jan 21, 2009
Pegaptanib (Macugen) is an injection that you have in your eyeball. Two studies have found that injections every month or so can lower the chance of your guardian.co.uk,

BUYINS.NET: Market Maker Surveillance Report. Top 6 Winning Stocks ...  -  Feb 3, 2009
The company also offers Macugen for the treatment of neovascular age-related macular degeneration; and Novantrone, an anthracenedione used as an intravenous Trading Markets (press release),

Pharma Earnings In Q4 - Healthy Or Ailing?  -  Jan 25, 2009
Gilead also earns royalties from anti-flu drug Tamiflu whose patent is expected to run till 2016 and Macugen, a treatment for wet macular degeneration, Trading Markets (press release),

For Pfizer, a Big Buy Could Be a Big Mistake  -  Jan 15, 2009
Pfizer also sells Macugen for wet age-related macular degeneration, but sales are modest. Could Pfizer overcome antitrust questions in a bid for Allergan, Motley Fool

Pfizer Reports Fourth-Quarter and Full-Year 2008 Results and 2009 ...  -  Jan 26, 2009
Exforge, 2251 1789 26 1300 1063 22 951 726 31 Macugen, Olmetec, Rebif and Spiriva) ANIMAL HEALTH 2825 2639 7 1168 1132 3 1657 1507 10 OTHER ** 1297 1355 MarketWatch (press release)

Gilead Sciences Q4 Net Income Jumps 41% On Strong HIV Drug Sales ...  -  Jan 27, 2009
Gilead also earns royalties from anti-flu drug Tamiflu whose patent is valid till 2016 and Macugen, a treatment for wet macular degeneration, Trading Markets (press release),

Spritze rettet das Augenlicht  -  Jan 29, 2009
Bleiben den Augenärzten also die beiden anderen Präparate (Markennamen: Lucentis und Macugen). „Mit Lucentis-Spritzen direkt ins Auge erreichen wir in 30 Oberhessische Presse,

SV Life Sciences Promotes Dr. David Guyer to Partner  -  Dec 2, 2008
The company also developed and gained FDA approval for Macugen, the first VEGF inhibitor approved by the US Food and Drug Administration to treat macular MarketWatch

Replidyne officer getting $390000 Denver Business Journal  -  Dec 11, 2008
Prior to Replidyne, Janjic spearheaded the creation of Macugen, a drug that treats a blinding disease called macular degeneration, for now-defunct Boulder Bizjournals.com,

UK government denies healthcare based on costs  -  Dec 5, 2008
...[6] The first drug, Macugen, was completely blocked, while the second, Lucentis, was limited to the approximately one in five disease sufferers who have a Spero News

Premium Company Profile - OSI Pharmaceuticals - New Research ...  -  Nov 14, 2008
The company has three marketed products, namely, Tarceva, Novantrone and Macugen for various indications in the areas of oncology, ophthalmology and Live-PR.com (Pressemitteilung),

Archemix Looks to Hitch Eli Lilly to Aptamer Express in New Deal  -  Oct 19, 2008
In recent years the FDA made its first aptamer drug approval for pegaptanib (Macugen), a treatment for age-related macular degeneration. Xconomy,

Boost for sight saving drugs in Somerset  -  Oct 1, 2008
..."Every day that NICE delays allowing Macugen to be prescribed is a day when another 100 people across the country start to lose their sight. Sommerset County Gazette,

Gene discovery may help hunt for blindness cure  -  Oct 7, 2008
Profile, Research, Stock Buzz), and Pfizer's (PFE.N: Quote, Profile, Research, Stock Buzz) Macugen. (Reporting by Ben Hirschler; Editing by Dominic Evans. Reuters

Hallazgo llevaría a descubrir cura a ceguera  -  Oct 8, 2008
Esta forma de la enfermedad puede ser tratada con medicamentos modernos como Lucentis, de Novartis y Genentech, y Macugen, de Pfizer. La Nación Costa Rica,

Descoberta genética pode ajudar no combate a degeneração macular  -  Oct 7, 2008
Essa forma da doença pode ser combatida por meio de medicamentos modernos como o Lucentis, da Novartis e da Genentech, eo Macugen, da Pfizer's. O Globo Online,

ファイザー�?加齢黄斑変性症治療剤「マクジェン(R)�?新発売  -  Oct 13, 2008
...�?��?��?�り�?�?��?�増加率�?�ら�?�る�?�2008年�?�患者数�?�約52000人�?�推定�?�れ�?��?�。 - 製�?�??：マクジェン(R)�?�?体内注射用キット0.3mg（MACUGEN(R)IVT Inj. KIT 0.3mg） Japan Corporate News Network (プレスリリース),

NICE dismisses Macugen appeal  -  Sep 12, 2008
However, in the same statement, it said anti-VEGF drug Macugen would not be made available to NHS patients. The chairman of the Scientific Committee of the Optician Online,

NICE endorses Novartis eye drug Lucentis  -  Aug 26, 2008
A second drug, Macugen from Pfizer, was rejected as not cost-effective. "Lucentis is an expensive drug, costing more than 10000 pounds for each eye treated. International Herald Tribune,

Sight-saving treatment could help hundreds of elderly patients  -  Sep 2, 2008
Another drug, pegaptanib (Macugen), however, has not been made available. Andrew Dillon, NICE chief executive, said: “Lucentis is an expensive drug, Borehanwood Times,

Steps Can Lower Risks Of Eye Disease  -  Aug 26, 2008
Injections of medications (Lucentis, Avastin and Macugen) into the eye stop the abnormal blood vessels from growing and work amazingly well. The Morning News,

Nueva inyección más segura contra la DMAE  -  Sep 15, 2008
Macugen, la inyección intravítrea para el tratamiento de la Degeneración Macular Asociada a la Edad (DMAE) ha cambiado su formato para facilitar su PR Noticias (Comunicado de prensa),

英 ‘루센티스’ 급여 최종권고  -  Aug 29, 2008
...�? 비해 8000파운드(약 1593만�?)는 �?� 저렴한 것으로 추정�?�다. 한편, 화�?��?�?� AMD 치료제 ‘마쿠젠’(Macugen, pegaptanib)�?� �?�번�? 급여권고를 받는�?� 실패했다. 디지틀보사,

Medicamento anticeguera provoca controversia en GB  -  Aug 30, 2008
El otro 3%, que son alérgicos a Lucentis, pueden escoger una medicina alternativa: Macugen, que también es muy cara y es producida por el otro gigante esmas,

El director de la Unidad Médica de PFIZER (PFE.NY  -  Sep 11, 2008
Última noticiaEmpresas.- Pfizer facilita a los internautas videojuegos gratuitos para luchar contra el tabaquismo Ver más resumen noticias perfil gráficos El País (España),

OSI Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript  -  Jul 23, 2008
We signed a definitive agreement with a new company, led largely by the Eyetech sales leadership, to transfer the Macugen business in a deal focused on Seeking Alpha,

Pfizer Reports Second-Quarter 2008 Results  -  Jul 23, 2008
ALL OTHER 619 1025 (40) 181 665 (73) 438 360 22 ZYRTEC / ZYRTEC D 8 385 (98) 8 385 (98) - - - - ALLIANCE REVENUE (Aricept, Exforge, Macugen, Mirapex, FOXBusiness

Test-Aankoop lanceert nieuw geneesmiddel!  -  Jul 31, 2008
De communicatie rond Macugen is daar een sterk voorbeeld van. Macugen is een voorschriftplichtig geneesmiddel tegen maculadegeneratie. Test-Aankoop.be,

�?�乙二醇化蛋白质类�?�物或将改�?�现有生物工程�?�物市场�?�貌  -  Aug 4, 2008
2005年，FDA�?�批准由辉瑞公�?�研制的治疗�?年黄斑�?�性的新PEG制剂Macugen 中国生物技术信�?�网,

2008-07-02 20:07:16 - www.companiesandmarkets.com adds new report ...  -  03 Jul 2008
The company has three marketed products, namely, Tarceva, Novantrone and Macugen for various indications in the areas of oncology, ophthalmology and PR-Inside.com (Pressemitteilung),

Learn about the World Ophthalmic Pharmaceutical Drugs Market  -  Jun 27, 2008
FDA Approval for Lumigan(r) II-69 Allergan's Ganfort(r) Receives Pan European License II-69 Pfizer Receives Approval from EC to Market Macugen(r) II-70 Market Wire (press release)

Eyeing up opthalmic opportunities  -  Jun 30, 2008
Injecting a drug into the eye may sound risky to most people but is, in fact, routine and the preferred route for antiangiogenic drugs, such as Macugen Pharmaceutical Technology Europe,

Exercises to Try That Spare the Knees  -  Jun 28, 2008
Should she take the newly approved Macugen treatment for this condition? - PC ANSWER: The macula is a circular area of the retina smaller than a very small RedOrbit,

Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals  -  Jun 18, 2008
Medical Affairs and Medical Strategy at Eyetech Pharmaceuticals, and had been integral to the team that developed Macugen(TM) and brought it to market. Earthtimes (press release),

Macugen can boost visual acuity  -  May 29, 2008
Macugen can maintain or improve visual acuity in patients with neovacular age-related macular degeneration, according to a study presented at the recent Optician Online,

Off-label use of bevacizumab raises medical and ethical concerns ...  -  May 29, 2008
In addition, "the availability of registered drugs such as ranibizumab (Lucentis, Genentech) and pegaptanib (Macugen, OSI/Pfizer) raises further ethical OSN SuperSite (subscription),

BRVO patients improve after injections of anti-VEGF agent  -  May 5, 2008
John J. Wroblewski, MD, and colleagues prospectively evaluated the safety and efficacy of 0.3-mg and 1-mg injections of Macugen (pegaptanib sodium, OSN SuperSite (subscription),

Combined therapy appears effective in treating retinal vascular ...  -  May 23, 2008
The patients were treated off-label with standard doses of Avastin (bevacizumab, Genentech), Lucentis (ranibizumab, Genentech) or Macugen (pegaptanib sodium OSN SuperSite (subscription),

OSI Pharmaceuticals Announces First Quarter 2008 Financial Results  -  May 6, 2008
The Company also announced that it has signed a term sheet with an undisclosed third party for the divestiture of Macugen ® and anticipates that this Business Wire (press release),

Cimzia ® , Utilizing Enzon’s Pegylation Technology, Approved in the US  -  23 Apr 2008
Adagen and Oncaspar, others for which we receive royalties, PEG-INTRON, Pegasys, and Macugen, as well as other products currently in development. Business Wire (press release),

NICE publishes FAD endorsing Lucentis on the NHS  -  Apr 2, 2008
In December, it published new draft guidance that again rejected Pfizer’s Macugen but this time recommended the use of Lucentis on the NHS for the “first Pharma Times (subscription),

Drug to help save sight of thousands in North Wales  -  Apr 2, 2008
But it will reject another drug – Macugen – as not cost-effective. The drug is already approved in Scotland. More than 1000 people in Wales are diagnosed Daily Post,

Justice In Sight For Thousands At Risk Of Blindness As Barriers To ...  -  Apr 3, 2008
While Lucentis will be available to patients on the NHS, NICE has not recommended another anti-VEGF drug Macugen, for wet-AMD, despite calls from RNIB to Medical News Today (press release),

New drug to help save sight of thousands  -  Apr 1, 2008
It rejects another drug – Macugen (pegaptanib) – as not cost-effective. If there are no appeals, final guidance will be published in June and the NHS is ic Wales,

Thousands to keep sight after drug U-turn  -  Apr 1, 2008
Another drug, Macugen, is not recommended for use on the NHS at all as it is not deemed effective enough to justify the cost. Telegraph.co.uk,

SIGHT-SAVING DRUG TO GET SEAL OF APPROVAL FROM HEALTH INSTITUTE  -  Apr 2, 2008
The institute is due to reject another drug, called Macugen (pegaptanib), as not cost-effective. If there are no appeals against this, the final guidance Express & Echo,

After two-year delay 'left 20000 people blind', patients finally ...  -  Apr 1, 2008
...can be offered to the majority of sufferers whether it is the first or second eye affected, but rejects the use of another drug, Macugen, on the NHS. Daily Mail,

Gilead Sciences - A Balm Or A Bane  -  Mar 29, 2008
Gilead also earns royalties from anti-flu drug Tamiflu whose patent is valid till 2016 and Macugen, a treatment for wet macular degeneration, RTT News,

SIGHT-SAVER DRUG APPROVED  -  Apr 2, 2008
Nice has not approved a similar drug, Macugen, which is also available in Scotland. In August last year, the Leicester Mercury reported that up to 1000 Leicester Mercury,

A caring eye for detail  -  Mar 3, 2008
For a specialist such as Armbrecht, Lucentis (ranibizumab) is a breakthrough, even more so than Macugen (pegaptanib), another recently introduced drug. Scotsman,

Pfizer says may win six Japan approvals this year  -  Feb 27, 2008
Salomon Azoulay, head of Pfizer's Japan development, told reporters that other drugs that may gain approval include Macugen for age-related vision problems Reuters

Eye condition 'doubles chance of heart attacks'  -  Feb 27, 2008
Treatments for wet AMD, such as Lucentis, Macugen and Avastin, are known as anti-VEGF treatments because they prevent the growth of blood vessels by Telegraph.co.uk,

Eye disease "increases death risk"  -  Feb 28, 2008
The experts from the University of Sydney also looked at medications for AMD, such as Macugen and Lucentis, and found that in some cases they can actually Nursing in Practice,

Priced out of the UK market  -  Feb 22, 2008
Although it has not made a final determination, in June 2007 the NICE rejected the use of Macugen, the less expensive drug. Lucentis can be used, Nature.com (subscription),

Success for campaign to make macular disease drugs available in ...  -  Feb 13, 2008
Elsewhere in the UK the sight-saving drugs Macugen and Lucentis are prescribed according to a postcode lottery. Pat had never heard of the condition before icSeftonandWestLancs,

Dickinson's Trial Runners is expanding  -  Feb 25, 2008
The trial tested a drug called Macugen which fights macular degeneration. Macugen has been approved by the FDA and is currently available for prescription. Dickinson Press,

Fight for treatment to save man's sight  -  Feb 28, 2008
Both Lucentis and Macugen eye drugs have been licensed to be used in the UK by people suffering from wet AMD but under the PCT's funding policy, Advertiser 24,

OSI Pharmaceuticals Announces Year End 2007 Financial Results  -  Feb 21, 2008
Our eye disease business consists principally of Macugen(R) (pegaptanib sodium injection), our marketed product for the treatment of wet age-related macular Centre Daily Times,

Pensioner left to go blind due to lack of funding  -  Feb 13, 2008
With the sight in his right eye rapidly deteriorating, he has made a desperate appeal to the PCT to agree to pay for sight-saving drugs Lucentis or Macugen The Argus.co.uk,

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.